Effects of ranibizumab in zoneⅠand zoneⅡretinopathy of prematurity patients_Chinese Journal of Ocular Fundus Diseases

Authors：

ChenYi , FengJing , MengXianfen , 邓洵 , 尹虹 , 梁建宏 ,  黎晓新

Department of Ophthalmology, Peking University People's Hospital, Beijing 100044, China;

Corresponding author：

黎晓新, Email: drli_xiao_xin@163.com

Keywords：

Retinopathy of prematurity/drug therapy; Angiogenesis inhibitors/therapeutic use; Antibodies; monoclonal/therapeutic use

DOI：

10.3760/cma.j.issn.1005-1015.2015.01.003

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To evaluate the effectiveness and complications associated with the use of ranibizumab in the treatment of ZoneⅠand ZoneⅡretinopathy of prematurity (ROP). Methods Data from patients of ROP who had received intravitreal ranibizumab (IVR) injections in Peking University People's Hospital for the treatment of ROP from July 2012 to December 2013 were collected. In total, 151 eyes from 85 patients (56 male and 29 female) were analyzed. The mean birth weight was (1438.6±334.5) g (range:790-2280 g), mean gestational age was (30.1±2.0) weeks (range:25-37 weeks), mean age at the time of intervention was (37.0±6.2) gestational weeks (range:32-45 weeks), mean follow-up was (4.9±3.3) months (range:1.4-20.8 months). The main outcome measures were the regression of ROP and the complications that were associated with the IVR injections. Results After receiving IVR injections, 120 eyes (79.5%) exhibited ROP regression after single injection. Twenty-six eyes (17.2%) required additional laser treatment for ROP regression after the absence of a positive response to the IVR injections. Five eyes (3%) progressed to stage 4 ROP and required vitrectomy to reattach the retinas. Fifty of 120 eyes which were regressed after single IVR had recurrence of ROP and need additional laser or additional IVR. All of the eyes (100.0%) had attached retinas after the various treatments that they received. No notable systemic complications related to the IVR injections were observed. Conclusions IVR injection seems to be an effective and well-tolerated method to treat ZoneⅠand ZoneⅡROP. Recurrence of ROP is common and long-term follow up may be needed.

Citation： ChenYi, FengJing, MengXianfen. Effects of ranibizumab in zoneⅠand zoneⅡretinopathy of prematurity patients. Chinese Journal of Ocular Fundus Diseases, 2015, 31(1): 6-9. doi: 10.3760/cma.j.issn.1005-1015.2015.01.003 Copy

1.	Early Treatment for Retinopathy of Prematurity Cooperative Group, Good WV, Hardy RJ, et al. Final visual acuity results in the early treatment for retinopathy of prematurity study[J]. Arch Ophthalmol, 2010, 128(6):663-671.
2.	Palmer EA, Hardy RJ, Dobson V, et al. 15-year outcomes following threshold retinopathy of prematurity:final results from the multicenter trial of cryotherapy for retinopathy of prematurity[J]. Arch Ophthalmol, 2005, 123(3):311-318.
3.	Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer[J].N Engl J Med, 2004, 350(23):2335-2342.
4.	Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal bevacizumab(Avastin)[J]. Ophthalmology, 2007, 114(5):855-859.
5.	Mintz-Hittner HA, Kennedy KA, Chuang AZ, et al.Efficacy of intravitreal bevacizumab for stage 3+retinopathy of prematurity[J].N Engl J Med, 2011, 364(7):603-615.
6.	Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal ranibizumab (Lucentis)[J]. Ophthalmology, 2007, 114(12):2179-2182.
7.	中华医学会.早产儿治疗用氧和视网膜病变防治指南[J].中华围产医学杂志, 2006, 9 (6):363-364.
8.	International Committee for the Classification of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity revisited[J]. Arch Ophthalmol, 2005, 123(7):991-999.
9.	Wu WC, Kuo HK, Yeh PT, et al.An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in Taiwan[J]. Am J Ophthalmol, 2013, 155(1):150-158.
10.	Stahl A, Hellstrom A, Smith LE.Insulin-like growth factor-1 and anti-vascular endothelial growth factor in retinopathy of prematurity:has the time come?[J]. Neonatology, 2014, 106(3):254-260.
11.	Sato T, Shima C, Kusaka S, et al.Vitreous levels of angiopoietin-1 and angiopoietin-2 in eyes with retinopathy of prematurity[J]. Am J Ophthalmol, 2011, 151(2):353-357.
12.	Xiang N, Zhao MJ, Li XY, et al. Redundant mechanisms for vascular growth factors in retinopathy of prematurity in vitro[J]. Ophthalmic Res, 2011, 45(2):92-101.
13.	Gaudreault J, Fei D, Rusit J, et al. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration[J]. Invest Ophthalmol Vis Sci, 2005, 46(2):726-733.
14.	Miyake T, Sawada O, Kakinoki M, et al.Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes[J]. Invest Ophthalmol Vis Sci, 2010, 51(3):1606-1608.
15.	Tahija SG, Hersetyati R, Lam GC, et al. Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zoneⅠand posterior zoneⅡretinopathy of prematurity[J].Br J Ophthalmol, 2014, 98(4):507-512.

1. Early Treatment for Retinopathy of Prematurity Cooperative Group, Good WV, Hardy RJ, et al. Final visual acuity results in the early treatment for retinopathy of prematurity study[J]. Arch Ophthalmol, 2010, 128(6):663-671.
2. Palmer EA, Hardy RJ, Dobson V, et al. 15-year outcomes following threshold retinopathy of prematurity:final results from the multicenter trial of cryotherapy for retinopathy of prematurity[J]. Arch Ophthalmol, 2005, 123(3):311-318.
3. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer[J].N Engl J Med, 2004, 350(23):2335-2342.
4. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal bevacizumab(Avastin)[J]. Ophthalmology, 2007, 114(5):855-859.
5. Mintz-Hittner HA, Kennedy KA, Chuang AZ, et al.Efficacy of intravitreal bevacizumab for stage 3+retinopathy of prematurity[J].N Engl J Med, 2011, 364(7):603-615.
6. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal ranibizumab (Lucentis)[J]. Ophthalmology, 2007, 114(12):2179-2182.
7. 中华医学会.早产儿治疗用氧和视网膜病变防治指南[J].中华围产医学杂志, 2006, 9 (6):363-364.
8. International Committee for the Classification of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity revisited[J]. Arch Ophthalmol, 2005, 123(7):991-999.
9. Wu WC, Kuo HK, Yeh PT, et al.An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in Taiwan[J]. Am J Ophthalmol, 2013, 155(1):150-158.
10. Stahl A, Hellstrom A, Smith LE.Insulin-like growth factor-1 and anti-vascular endothelial growth factor in retinopathy of prematurity:has the time come?[J]. Neonatology, 2014, 106(3):254-260.
11. Sato T, Shima C, Kusaka S, et al.Vitreous levels of angiopoietin-1 and angiopoietin-2 in eyes with retinopathy of prematurity[J]. Am J Ophthalmol, 2011, 151(2):353-357.
12. Xiang N, Zhao MJ, Li XY, et al. Redundant mechanisms for vascular growth factors in retinopathy of prematurity in vitro[J]. Ophthalmic Res, 2011, 45(2):92-101.
13. Gaudreault J, Fei D, Rusit J, et al. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration[J]. Invest Ophthalmol Vis Sci, 2005, 46(2):726-733.
14. Miyake T, Sawada O, Kakinoki M, et al.Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes[J]. Invest Ophthalmol Vis Sci, 2010, 51(3):1606-1608.
15. Tahija SG, Hersetyati R, Lam GC, et al. Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zoneⅠand posterior zoneⅡretinopathy of prematurity[J].Br J Ophthalmol, 2014, 98(4):507-512.

Chinese Journal of Ocular Fundus Diseases

Effects of ranibizumab in zoneⅠand zoneⅡretinopathy of prematurity patients

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content